Oxygen therapy for autism is one of the most debated topics in hyperbaric medicine. A single randomized controlled trial from 2009 reported improvements in children with autism spectrum disorder after HBOT, but those results have never been replicated. The Undersea and Hyperbaric Medical Society does not recognize autism as an approved indication. Parents continue to pursue it, clinics continue to offer it, and the scientific community remains divided.
Autism spectrum disorder (ASD) affects roughly 1 in 36 children in the United States. It is a neurodevelopmental condition with no cure and limited treatment options, particularly for core symptoms like social communication difficulties and repetitive behaviors. This is the landscape that drives families toward alternative therapies, including hyperbaric oxygen.
Key Takeaways
- One RCT exists: Rossignol et al. (2009) reported improvements in 62 children with autism after 40 HBOT sessions at 1.3 ATA.
- Results have not been replicated in any subsequent controlled trial. A 2025 meta-analysis found insufficient evidence to recommend HBOT for ASD.
- Not FDA-approved or UHMS-recognized. No major medical body endorses HBOT for autism.
- Proposed mechanisms include reduced neuroinflammation, improved cerebral perfusion, and mitochondrial support.
- Cost is entirely out of pocket, typically ,000 to ,000 for a standard course of treatment.
The Rossignol 2009 Trial
The landmark study in this space was a multicenter randomized controlled trial published by Rossignol et al. in BMC Pediatrics in 2009. It remains the most cited piece of evidence for HBOT in autism.
Study Design
The trial enrolled 62 children with autism aged 2 to 7 years. They were randomly assigned to one of two groups:
- Treatment group (33 children): 40 one-hour sessions of HBOT at 1.3 ATA with 24% oxygen
- Control group (29 children): 40 one-hour sessions at 1.03 ATA with ambient air (near-placebo conditions)
Sessions were administered twice daily, with at least 4 hours between sessions, 5 days per week over 4 consecutive weeks.
Results
The treatment group showed statistically significant improvements in several areas as rated by clinicians and parents:
- Overall functioning (Clinical Global Impression scale)
- Receptive language
- Social interaction
- Eye contact
- Sensory and cognitive awareness
The study also found a significant reduction in C-reactive protein levels, suggesting an anti-inflammatory effect (Rossignol et al., 2009. DOI: 10.1186/1471-2431-9-21).
“The Rossignol trial is the only randomized controlled trial reporting effectiveness of HBOT for autism. Those results have yet to be repeated.”
Criticisms
The study has drawn substantial criticism:
- Low pressure, low oxygen: The protocol used only 1.3 ATA with 24% oxygen, which barely qualifies as hyperbaric treatment. Some researchers question whether the oxygen dose was sufficient to produce meaningful biological effects.
- Subjective outcomes: Most improvements were based on parent and clinician ratings, which are susceptible to placebo effects and expectation bias.
- Small sample size: With only 62 children, the study lacked statistical power to draw definitive conclusions.
- No replication: Multiple subsequent studies have failed to reproduce these findings.
Proposed Mechanisms
Researchers have proposed several ways HBOT could theoretically benefit children with autism:
- Neuroinflammation reduction: Some children with autism show elevated markers of brain inflammation. HBOT has anti-inflammatory properties that could help modulate this.
- Cerebral hypoperfusion: Brain imaging studies have found reduced blood flow in certain brain regions of children with ASD. HBOT increases cerebral perfusion and could improve function in underperfused areas.
- Mitochondrial dysfunction: A subset of children with autism have measurable mitochondrial abnormalities. HBOT supports mitochondrial energy production by increasing oxygen availability.
- Oxidative stress modulation: While this sounds counterintuitive (HBOT increases oxygen), controlled exposure may upregulate the body’s own antioxidant defenses through a process called hormesis.
These mechanisms are biologically plausible but remain theoretical. Having a reasonable explanation for how something could work is not the same as proving it does work.
What the Broader Evidence Shows
A 2017 systematic review examined the full body of evidence on HBOT for autism and concluded that case series and randomized controlled trials show no consistent evidence to support the benefit of HBOT for children with ASD.
A 2025 meta-analysis published in the Journal of Affective Disorders evaluated the effectiveness of HBOT in children and adolescents with autism spectrum disorders. The analysis found that while some individual studies reported improvements in specific domains, the overall evidence was insufficient to recommend HBOT as a treatment for ASD.
The Association for Science in Autism Treatment (ASAT) has reviewed the evidence and does not endorse HBOT for autism. The UHMS does not list autism among its approved indications. NHS England does not commission HBOT for autism.
The Controversy
Despite the weak evidence base, HBOT clinics actively market their services to families of children with autism. This creates a difficult situation:
- Parents are desperate for anything that might help their child
- Anecdotal reports from other parents can be compelling
- The treatment is low-risk in terms of physical safety
- The financial cost is substantial and entirely out of pocket
- Time and resources spent on HBOT could be directed toward therapies with stronger evidence (ABA, speech therapy, occupational therapy)
Some clinicians argue that the absence of strong evidence is not the same as evidence of absence. Others counter that a single positive RCT from 2009 that has never been replicated should not drive clinical decisions for vulnerable children.
Typical Protocols Used
| Parameter | Rossignol Protocol | Clinical Practice Range |
|---|---|---|
| Pressure | 1.3 ATA | 1.3 to 1.5 ATA |
| Oxygen | 24% | 24% to 100% |
| Session length | 60 minutes | 60 minutes |
| Sessions | 40 | 40 to 80 |
| Frequency | Twice daily | Once to twice daily |
Cost
HBOT for autism is never covered by insurance. Families pay entirely out of pocket.
- Per session: to
- 40-session course: ,000 to ,000
- Extended courses (80 sessions): ,000 to ,000
- Home chambers: ,000 to ,000 for purchase (1.3 ATA soft-shell units)
Some families purchase mild hyperbaric chambers for home use, which eliminates per-session costs but limits pressure to 1.3 ATA. For a more detailed look at HBOT protocols and evidence for autism specifically, see our dedicated guide on hyperbaric chamber for autism.
Frequently Asked Questions
Does HBOT cure autism?
No. No therapy cures autism. HBOT is explored as a potential way to improve specific symptoms, not as a cure for the condition itself.
Is HBOT safe for children with autism?
At the low pressures used (1.3 to 1.5 ATA), HBOT is considered physically safe for children. The main risks are ear discomfort from pressure changes and, rarely, mild sinus issues. The greater concern is financial and opportunity cost rather than physical risk.
What age should a child start HBOT for autism?
The Rossignol trial included children aged 2 to 7. Some clinics treat children as young as 18 months, though there is no evidence establishing an optimal age. Younger children may have more difficulty tolerating the chamber environment.
Should I try HBOT for my child with autism?
This is a personal decision that should be made with full awareness of the evidence limitations. The single positive RCT has not been replicated. Evidence-based therapies like applied behavior analysis, speech therapy, and occupational therapy have much stronger research support and should be prioritized.
References
- Rossignol, D.A., et al. (2009). Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatrics, 9, 21. DOI: 10.1186/1471-2431-9-21
- Granpeesheh, D., et al. (2010). Randomized trial of hyperbaric oxygen therapy for children with autism. Research in Autism Spectrum Disorders, 4(2), 268-275. DOI: 10.1016/j.rasd.2009.09.014
- Xiong, T., et al. (2016). Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD010922.pub2
- Luo, Y., et al. (2025). The effectiveness of hyperbaric oxygen therapy in children and adolescents with autism spectrum disorders: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 136, 111178.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
